Silence Therapeutics (NASDAQ:SLN) Shares Down 4.9%

Silence Therapeutics plc (NASDAQ:SLN)’s stock price fell 4.9% during trading on Wednesday . The company traded as low as $18.96 and last traded at $18.98. 21,063 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 194,638 shares. The stock had previously closed at $19.95.

Analyst Upgrades and Downgrades

Several research firms recently commented on SLN. Chardan Capital reissued a “buy” rating and set a $42.00 target price on shares of Silence Therapeutics in a research note on Friday, May 17th. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Thursday, June 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Silence Therapeutics in a research note on Monday, April 22nd.

Silence Therapeutics Stock Performance

The business has a fifty day simple moving average of $21.35 and a 200 day simple moving average of $20.95. The stock has a market cap of $545.92 million, a price-to-earnings ratio of -16.47 and a beta of 1.34.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.18. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. The business had revenue of $15.73 million for the quarter, compared to analysts’ expectations of $4.53 million. On average, equities research analysts anticipate that Silence Therapeutics plc will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC raised its position in shares of Silence Therapeutics by 10.5% in the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after buying an additional 667 shares during the period. Parkman Healthcare Partners LLC grew its stake in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,063 shares in the last quarter. Lynx1 Capital Management LP acquired a new stake in shares of Silence Therapeutics during the third quarter valued at about $2,315,000. Vivo Capital LLC acquired a new stake in shares of Silence Therapeutics during the fourth quarter valued at about $8,862,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Silence Therapeutics during the first quarter valued at about $13,575,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.